Piramal to Acquire HPAPI CDMO Ash Stevens

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
Volume 11
Issue 9

Piramal Enterprises has entered into an agreement to acquire 100% stake in Ash Stevens all by cash for a consideration of $42.95 million plus an earn-out consideration capped at $10 million.

Piramal Enterprises announced that it has entered into an agreement to acquire 100% stake in Ash Stevens all by cash for a consideration of $42.95 million plus an earn-out consideration capped at $10 million. The transaction is not subject to any regulatory approvals and Piramal expects to close this deal by end of August 2016.

Ash Stevens is a contract development and manufacturing (CDMO) based in Riverview, Michigan serving several bio/pharmaceutical companies worldwide. The CDMO has more than 60,000 square feet facilities, eight chemical drug development and production laboratories, and six full-scale production areas.

Ash Stevens also works with high-potency anticancer agents and other highly potent drugs. Its state-of-the-art manufacturing facility in Michigan is equipped with the necessary engineering and containment controls for the safe handling and cGMP manufacture of small and large-scale HPAPIs, with occupational exposure limits (OELs) ≤ 0.1microggram/m3. The facility has been approved by regulators from US, EU, Australia, Japan, Korea, and Mexico.

Wells Fargo Securities, LLC will serve as exclusive financial advisor to Ash Stevens, with legal counsel provided by Morrison & Foerster LLP.

Source: Piramal Enterprises

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content